61 results on '"Bay-Jensen Anne-Christine"'
Search Results
2. Evaluating the inhibition of IL-17A and TNFα in a cartilage explant model cultured with Th17-derived cytokines
3. Development and validation of a machine learning-supported strategy of patient selection for osteoarthritis clinical trials: the IMI-APPROACH study
4. Biomarkers for osteoarthritis: Current status and future prospects
5. Dynamic compression inhibits cytokine-mediated type II collagen degradation
6. A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis
7. Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study
8. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers
9. Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases
10. Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: Data from two phase III clinical trials
11. Serological CTX-II does not measure the same as urinary CTX-II
12. Evaluation of serum ARGS neoepitope as an osteoarthritis biomarker using a standardized model for exercise-induced cartilage extra cellular matrix turnover
13. Association between type III collagen degradation and local tissue damage of a single joint
14. Expanding the citrullinome of synovial fibrinogen from rheumatoid arthritis patients
15. Osteoarthritis phenotypes and novel therapeutic targets
16. Tofacitinib and TPCA-1 exert chondroprotective effects on extracellular matrix turnover in bovine articular cartilage ex vivo
17. Protein biomarkers associated with pain mechanisms in osteoarthritis
18. Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development
19. Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice?
20. Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non–Small Cell Lung Cancer
21. Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD
22. Neutrophil activity in serum as a biomarker for multiple sclerosis
23. Biomarkers of Tissue Turnover and Systemic Inflammation Are Associated with Disease Severity and Activity in Patients with Hidradenitis Suppurativa
24. 51563 TNF-α and TGF-β synergistically promote fibrogenesis in an In Vitro Model of Fibro-inflammation
25. 52771 From Local Skin Manifestation to Systemic Tissue Turnover: Serological Collagen Biomarkers Provide Valuable Information on Skin Diseases Arising from Mutations in Collagen Genes
26. 51826 PRO-C22 - A Novel Serological Biomarker of Tissue Damage is Associated with Disease Severity, Disease Activity, and Systemic Inflammation in Patients with Hidradenitis Suppurativa
27. 51783 A novel biomarker of type VII collagen degradation is increased in patients with atopic dermatitis and lowered when receiving immunosuppressant treatment.
28. Molecular serum and urine marker repertoire supporting clinical research on joint diseases
29. Glucocorticoids exert context-dependent effects on cells of the joint in vitro
30. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—Increased serum CIIM in subjects with severe radiographic osteoarthritis
31. Tu1758 PRO-C11 AND PRO-C16 ARE MARKERS OF INTESTINAL FIBROSIS AND ARE ASSOCIATED WITH MRE-CONFIRMED INTESTINAL STRICTURES – RESULTS FROM THE IMAGEKIDS STUDY
32. Sa2034 CPA9-HNE: A NEUTROPHIL-SPECIFIC FRAGMENT OF CALPROTECTIN MEASURED IN SERUM CAN MONITOR ENDOSCOPIC AND CLINICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS
33. Sa2030 SERUM BIOMARKERS OF PROTEOLYTIC TISSUE DESTRUCTION, FORMATION AND MACROPHAGE ACTIVITY CAN DISCERN PATIENTS WITH IBD ACCORDING TO INFLIXIMAB TREATMENT NON-RESPONSE OR RESPONSE
34. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease?
35. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?
36. 198 - Biochemical markers in bone disease
37. Targeting ADAMTS-5 for osteoarthritis: Promise and challenges
38. Mo1523: BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
39. Mo1524: SEROLOGICAL BIOMARKERS OF TYPE VI AND XXII COLLAGEN FORMATION PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE
40. Su1655: ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN'S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY
41. Su1526: TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
42. Sa1115: EVALUATION OF SERUM PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN, CITRULLINATED VIMENTIN AND CALPROTECTIN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
43. 581 A FIBROSIS RESOLUTION BIOMARKER: DETECTION OF PROTEASE DEGRADED, AND CROSS-LINKED TYPE III COLLAGEN DEGRADATION FRAGMENTS RELEASED FROM THE FIBROTIC ECM, BY A NEO-EPITOPE SPECIFIC BLOOD-BASED BIOMARKER IN LIVER FIBROSIS
44. Su435 BIOMARKERS OF EXTRACELLULAR MATRIX REMODELING IDENTIFY RESPONDERS TO VEDOLIZUMAB THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS IN THE GEMINI I STUDY
45. Sa460 NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY FOR IBD
46. Fr206 NOVEL BLOOD-BASED BIOMARKERS FOR MONITORING DISEASE PROGRESSION IN ADULT EOSINOPHILIC ESOPHAGITIS PATIENTS
47. FRI249 - Endotrophin, a hormone derived from type VI collagen, activates fibroblasts and drives fibrosis in the liver, lung, kidney, and heart
48. Contributors
49. Tu1789 - Tofacitinib and Cytokines of the Jak Signalling Pathway Protect Againts Extracellular Matrix (ECM) Destruction in an Intestinal Ex Vivo Model
50. Sa1798 - Platelet Activation by Activated Von Willebrand Factor is a Marker of Intestinal Wound Healing in Patietns with Crohns Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.